tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

SRPT Stock Latest News

RBC sees Makary interview as potentially positive for biotech stocks
The FlyRBC sees Makary interview as potentially positive for biotech stocks
3d ago
DYN
RNA
Sarepta price target lowered to $110 from $182 at Piper Sandler
PremiumThe Fly
Sarepta price target lowered to $110 from $182 at Piper Sandler
4d ago
SRPT
Sarepta price target lowered to $157 from $179 at BofA
PremiumThe Fly
Sarepta price target lowered to $157 from $179 at BofA
4d ago
SRPT
Sarepta Therapeutics: Buy Rating Affirmed on Promising LGMD Program Progress and Regulatory Advancements
PremiumRatings
Sarepta Therapeutics: Buy Rating Affirmed on Promising LGMD Program Progress and Regulatory Advancements
9d ago
SRPT
Cautious Hold Rating on Sarepta Therapeutics Amid Limited LGMD Market and ELEVIDYS Uncertainties
PremiumRatings
Cautious Hold Rating on Sarepta Therapeutics Amid Limited LGMD Market and ELEVIDYS Uncertainties
9d ago
SRPT
Sarepta Therapeutics’ Promising LGMD Pipeline and Regulatory Progress Support Buy Rating
PremiumRatingsSarepta Therapeutics’ Promising LGMD Pipeline and Regulatory Progress Support Buy Rating
9d ago
SRPT
Sarepta announces pipeline progress for limb-girdle muscular dystrophy subtypes
Premium
The Fly
Sarepta announces pipeline progress for limb-girdle muscular dystrophy subtypes
10d ago
SRPT
Walmart, Target initiated: Wall Street’s top analyst calls
Premium
The Fly
Walmart, Target initiated: Wall Street’s top analyst calls
14d ago
VZ
AXP
Sarepta price target lowered to $182 from $196 at Morgan Stanley
PremiumThe Fly
Sarepta price target lowered to $182 from $196 at Morgan Stanley
14d ago
SRPT
Sarepta initiated with an Overweight at Wells Fargo
PremiumThe Fly
Sarepta initiated with an Overweight at Wells Fargo
14d ago
SRPT
Sarepta price target lowered to $112 from $150 at Guggenheim
PremiumThe Fly
Sarepta price target lowered to $112 from $150 at Guggenheim
15d ago
SRPT
Sarepta price target lowered to $184 from $215 at Oppenheimer
PremiumThe Fly
Sarepta price target lowered to $184 from $215 at Oppenheimer
18d ago
SRPT
Positive Outlook for Sarepta Therapeutics Amid Favorable Trial Evaluations and Proactive Regulatory Response
PremiumRatingsPositive Outlook for Sarepta Therapeutics Amid Favorable Trial Evaluations and Proactive Regulatory Response
18d ago
SRPT
Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS
Premium
The Fly
Sarepta announces EU regulators temporarily halted dosing of ELEVIDYS
21d ago
SRPT
H.C. Wainwright sees increased uncertainty for Sarepta franchise
Premium
The Fly
H.C. Wainwright sees increased uncertainty for Sarepta franchise
21d ago
CHRO
SRPT
3 Best Value Stocks to Buy Now, 4/4/2025, According to Analysts 
PremiumMarket News
3 Best Value Stocks to Buy Now, 4/4/2025, According to Analysts 
21d ago
SUN
SRPT
Sarepta Therapeutics: Undervalued Stock with Strong US Market Potential Despite EMA Hold
PremiumRatings
Sarepta Therapeutics: Undervalued Stock with Strong US Market Potential Despite EMA Hold
21d ago
SRPT
Oppenheimer healthcare analysts hold analyst/industry conference call
PremiumThe Fly
Oppenheimer healthcare analysts hold analyst/industry conference call
21d ago
SRPT
Sarepta sinks 9% after Elevidys studies placed on hold in Europe
PremiumThe Fly
Sarepta sinks 9% after Elevidys studies placed on hold in Europe
22d ago
SRPT
Sarepta price target lowered to $183 from $202 at Needham
PremiumThe FlySarepta price target lowered to $183 from $202 at Needham
22d ago
SRPT
Sarepta study pause brings approvability risk in Europe, says RBC
Premium
The Fly
Sarepta study pause brings approvability risk in Europe, says RBC
22d ago
CHRO
SRPT
Sarepta clinical hold in Europe likely temporary, says Mizuho
Premium
The Fly
Sarepta clinical hold in Europe likely temporary, says Mizuho
22d ago
SRPT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >